PFE vs WMT: Which Is the Better Buy?
Side-by-side comparison of Pfizer Inc. and Walmart Inc. — fair value, conviction, valuation metrics, and QuantHub research signals.
Updated 2026-06-20.
Pfizer Inc. · Healthcare
$25.22
+2.8% upside to fair value
Grade B
VS
Walmart Inc. · Consumer Defensive
$117.18
-39.6% upside to fair value
Grade C
High Quality
QuantHub Verdict
PFE has more upside to fair value
(+2.8%).
PFE trades at a lower forward P/E
(19.2x).
These are model outputs — not personalized investment advice.
See all research →
Valuation & Fundamentals
| Metric |
PFE |
WMT |
| Current Price |
$25.22 |
$117.18 |
| Fair Value Estimate |
$25.92 |
$70.81 |
| Upside to Fair Value |
+2.8%
|
-39.6%
|
| Market Cap |
$143.7B |
$932.5B |
| Forward P/E |
19.2x
|
41.1x
|
| EV / EBITDA |
12.3x
|
20.7x
|
| Price / Sales |
2.3x
|
1.3x
|
| Price / FCF |
15.2x
|
74.3x
|
| Revenue Growth YoY |
+5.4%
|
+7.3%
|
| Gross Margin |
69.3%
|
25.0%
|
| Operating Margin |
23.4%
|
4.2%
|
| Return on Equity |
8.4%
|
24.3%
|
| Dividend Yield |
0% |
0% |
| FCF Yield |
6.6%
|
1.35%
|
| Analyst Consensus |
Hold
|
Strong Buy
|
Investment Thesis
Pfizer Inc. is a leading global biopharmaceutical company with a diversified portfolio dominated by its Biopharma prescription segment, which accounts for over 90% of revenue. The company benefits from a substantial scale, a broad product portfolio including top-selling drugs like Eliquis, Prevnar, and Paxlovid, and a strong manufacturing footprint. However, Pfizer faces challenges from declining…
Walmart Inc. operates as a leading discount retailer with a strong competitive moat built on scale, cost leadership, and advanced logistics and technology infrastructure. The company benefits from a diversified revenue base with Walmart U.S. contributing 69%, International 18%, and Sam's Club 13%. Despite solid revenue growth of 7.3% and earnings growth of 25.9% in the most recent quarter, the st…
Accumulation Zones
| Metric |
PFE |
WMT |
| Zone Low |
$19.44 |
$53.11 |
| Zone High |
$22.03 |
$60.19 |
| In Buy Zone? |
No
|
No
|